The Company

Sentinel Oncology was founded in 2005 and is a drug discovery company dedicated to the development of new therapeutics to treat cancer where there is an unmet medical need. The company’s portfolio comprises of programmes focused on the PI3K pathway (p70S6 Kinase), DNA repair (Checkpoint kinase 1), cell signalling (FLT-3) and features  a novel and innovative strategy for cancer treatment, “Targeted Synergy” that was developed with funding received from the Wellcome Trust’s Seeding Drug Discovery initiative.

 

Targeted Synergy is a first in class approach in which a single drug delivers two, synergistic activities, to the unique microenvironment of solid tumours. Find out more...

 

Sentinel has assembled a group of highly motivated investors and advisors that collectively bring complementary skills and experience in finance, biotech and drug discovery to lead the development of our drug pipeline. Our business objective is to out-license programmes with organisations seeking to progress candidate drugs through development and into clinical trials.

 

Sentinel Oncology is based in Cambridge, UK.